Observation On The Treatment Effect Of Fluimucil Combined With Symbicort In Patients With Stable Chronic Obstructive Pulmonary Disease

Objectives By observing patients with severe stable phase of Chronic obstructive pulmonary disease(COPD)in the application of Fluimucil(N-acetylcysteine,NAC)combined with Symbicort(Budesonide/Formoterol)post-treatment lung function(FEV1/FVC,FEV1% pred),blood gas analysis(PaCO2,PaO2),CAT score(Chronic obstructive pulmonary disease Assessment Test,CAT)and superoxide dismutase(SOD),interleukin-8(IL-8)and tumor necrosis factor alpha(TNF-?)were evaluated and the number of patients with acute exacerbation to evaluate the therapeutic effect of Fluimucil combined with Symbicort in the treatment of patients with stable chronic obstructive pulmonary disease.Methods 1 Observed subjects: We collected 128 patients with stable disease of moderate to severe chronic obstructive pulmonary disease who were stable after hospitalization in our hospital from December 01,2017 to December 31,2018.The enrolled patients were randomly divided into the observation group and the control group.All the enrolled patients were routinely given budesonide/formoterol inhalation 320ug/9 ug 2/day,and the observation group was given acetylcysteine on the basis of the control group.Acid effervescent tablets 600 mg 2 / day soaked water(two groups of treatment are 3 months).2Study Methods: General information on the enrolled patients: gender,age,height,weight,body mass index(BMI).Pulmonary function(FEV1/FVC,FEV1%pred),blood gas analysis(PaCO2,PaO2),CAT score,serum superoxide dismutase(SOD),interleukin-8(IL-8),tumor necrosis factor alpha(TNF-?)contentwere measured before and after treatment.Statistical analysis was performed using SPSS 22.0 statistical software,and graphs were drawn using GraphPad Prism 5,and the difference was statistically significant at P < 0.05.Results 1 Baseline characteristics 1)There was no significant difference in gender,age,height,weight and BIM between NAC group and control group(P>0.05).2)Pulmonary function(FEV1/FVC,FEV1% pred),blood gas analysis(PaCO2,PaO2),number of pulmonary function grades,and SOD,IL-8,TNF-?,CAT scores in the two groups before treatment,comparison between groups.The difference was not statistically significant(P>0.05).2 The efficacy analysis of the observation group 1)The FEV1/FVC,FEV1%pred,PaO2,SOD of the observation group were significantly higher than those before treatment(P<0.05);2)The CAT score,PaCO2,IL-8 of the observation group after treatment,TNF-? was significantly lower than before treatment(P<0.05).3 Analysis of the efficacy of the control group 1)After treatment,the FEV1/FVC,FEV1%pred,PaO2,SOD of the control group increased significantly(P<0.05);2)The CAT score,PaCO2,IL-8 of the control group after treatment,TNF-? was significantly lower than before treatment(P<0.05).4 The therapeutic effect of two groups were compared 1)The FEV1/FVC,FEV1%pred,PaO2,SOD of the NAC group were significantly higher than those of the control group after treatment,the difference was statistically significant(P<0.05);2)The CAT score,PaCO2,IL-8,and TNF-? in the observation group were significantly lower than those in the control group,and the difference was statistically significant(P<0.05);3)The number of acute exacerbations in the observation group was significantly lower thanthat in the control group during the treatment period,and the difference was statistically significant(P<0.05).5 Analysis of clinical efficacy(CAT score)by different factors 1)Analysis of the influence of different genders on the CAT score of the observation group.The results showed that the CAT score of female patients decreased more than that of male patients.After statistical analysis,the results were statistically significant.(P<0.05);2)Analysis of the influence of different age groups on the CAT score of the observation group.The results showed that the CAT score of the ?70-year-old patient group was lower than that of the >70-year-old patient group.After statistical analysis,the results were statistically significant(P<0.05).Conclusions 1 Fluimucil combined with Symbicort in patients with severe stable phase of COPD is effective and is superior to the single application of Symbicort.2 Fluimucil combined with Symbicort can effectively improve lung function,blood gas analysis,clinical symptoms,serum oxidative stress,inflammation levels in patients with severe stable COPD and can reduce the number of acute exacerbations in patients with stable COPD,and is superior to the single application of Symbicort.3 In the observation group patient the difference of gender and age has an effect on the clinical efficacy and the clinical effect was significant in female patients and patients aged 70 years.Figure6;Table18;Reference 130...